Oral chloroquine vs placebo
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).
Oral methotrexate showed no clear difference in secondary outcome: clinical flare compared with placebo (moderate certainty).
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
Oral hydroxychloroquine showed no clear difference in primary outcome: partial clinical response compared with placebo (low certainty).
5‐HT3 antagonists may leads to lower nausea ‐ intraoperative compared with placebo (low certainty).
It is very uncertain whether corticosteroids changes vomiting ‐ intraoperative compared with placebo (very low certainty).
Corticosteroids probably leads to lower nausea ‐ postoperative compared with placebo (moderate certainty).
Corticosteroids may leads to lower vomiting ‐ postoperative compared with placebo (low certainty).
It is very uncertain whether antihistamines changes nausea ‐ intraoperative compared with placebo (very low certainty).
It is very uncertain whether antihistamines changes vomiting ‐ postoperative compared with placebo (very low certainty).
Anticholinergics may leads to lower nausea ‐ intraoperative compared with placebo (low certainty).
It is very uncertain whether anticholinergics changes vomiting ‐ intraoperative compared with placebo (very low certainty).
It is very uncertain whether 5‐HT3 antagonists changes vomiting ‐ intraoperative compared with placebo (very low certainty).